Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Sulfinpyrazone | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Sulfinpyrazone | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Sulfinpyrazone | hsa00500 | Starch and sucrose metabolism | 6.17E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Sulfinpyrazone | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Sulfinpyrazone | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | Sulfinpyrazone | hsa00561 | Glycerolipid metabolism | 2.51E-02 | 2 | P51648, P23743 | ALDH3A2, DGKA | More | | Sulfinpyrazone | hsa00562 | Inositol phosphate metabolism | 7.30E-04 | 4 | P27987, Q96PE3, P19174, P42338 | ITPKB, INPP4A, PLCG1, PIK3CB | More | | Sulfinpyrazone | hsa00600 | Sphingolipid metabolism | 1.98E-03 | 5 | P07602, Q9BX95, Q13510, Q8TCT0, P15289 | PSAP, SGPP1, ASAH1, CERK, ARSA | More | | Sulfinpyrazone | hsa00620 | Pyruvate metabolism | 2.51E-02 | 2 | P40925, P51648 | MDH1, ALDH3A2 | More | | Sulfinpyrazone | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.78E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Sulfinpyrazone | hsa00730 | Thiamine metabolism | 2.27E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Sulfinpyrazone | hsa00830 | Retinol metabolism | 1.79E-03 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Sulfinpyrazone | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.24E-03 | 3 | O95363, P14868, Q15046 | FARS2, DARS, KARS | More | | Sulfinpyrazone | hsa00983 | Drug metabolism - other enzymes | 1.64E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Sulfinpyrazone | hsa01040 | Biosynthesis of unsaturated fatty acids | 2.92E-02 | 2 | P22307, Q9H5J4 | SCP2, ELOVL6 | More | | Sulfinpyrazone | hsa01100 | Metabolic pathways | 4.12E-02 | 12 | P15104, P51648, P42338, Q96PE3, P19174, P27987, Q13370, P40925, P23743, P43034, P09917, Q53FZ2 | GLUL, ALDH3A2, PIK3CB, INPP4A, PLCG1, ITPKB, PDE3B, MDH1, DGKA, PAFAH1B1, ALOX5, ACSM3 | More | | Sulfinpyrazone | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 7.30E-04 | 4 | Q92529, P19174, P42338, Q9NRA1 | SHC3, PLCG1, PIK3CB, PDGFC | More | | Sulfinpyrazone | hsa01522 | Endocrine resistance | 4.48E-02 | 4 | P22694, Q02750, Q9UM47, P46527 | PRKACB, MAP2K1, NOTCH3, CDKN1B | More | | Sulfinpyrazone | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | Sulfinpyrazone | hsa03013 | RNA transport | 7.27E-03 | 12 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, EIF4A2, TACC3, FXR1 | More | | Sulfinpyrazone | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Sulfinpyrazone | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Sulfinpyrazone | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Sulfinpyrazone | hsa03060 | Protein export | 1.90E-02 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | | Sulfinpyrazone | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Sulfinpyrazone | hsa04012 | ErbB signaling pathway | 9.49E-03 | 3 | Q92529, P19174, P42338 | SHC3, PLCG1, PIK3CB | More | | Sulfinpyrazone | hsa04014 | Ras signaling pathway | 1.34E-05 | 16 | Q02750, P42338, Q92529, P20827, Q15389, Q9NRA1, P49767, Q13009, P17252, Q7LDG7, P21359, P62879, P63218, P50151, P19174, P22694 | MAP2K1, PIK3CB, SHC3, EFNA1, ANGPT1, PDGFC, VEGFC, TIAM1, PRKCA, RASGRP2, NF1, GNB2, GNG5, GNG10, PLCG1, PRKACB | More | | Sulfinpyrazone | hsa04015 | Rap1 signaling pathway | 2.22E-03 | 9 | P20827, Q9NRA1, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, PDGFC, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | Sulfinpyrazone | hsa04020 | Calcium signaling pathway | 2.16E-02 | 4 | P27987, P19174, Q9NRA1, P49767 | ITPKB, PLCG1, PDGFC, VEGFC | More | | Sulfinpyrazone | hsa04062 | Chemokine signaling pathway | 2.01E-04 | 11 | P09769, P07948, P42338, P19174, Q92529, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, SHC3, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | | Sulfinpyrazone | hsa04064 | NF-kappa B signaling pathway | 8.68E-04 | 16 | Q13489, O00463, Q13546, P14778, P01584, P01375, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q8WV28, P24522, P09341, Q9UNE0, Q9NQC7 | BIRC3, TRAF5, RIPK1, IL1R1, IL1B, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, BLNK, GADD45A, CXCL1, EDAR, CYLD | More | | Sulfinpyrazone | hsa04066 | HIF-1 signaling pathway | 4.48E-02 | 4 | P17252, Q15389, Q02750, P46527 | PRKCA, ANGPT1, MAP2K1, CDKN1B | More | | Sulfinpyrazone | hsa04070 | Phosphatidylinositol signaling system | 3.19E-04 | 5 | P19174, P42338, P23743, Q96PE3, P27987 | PLCG1, PIK3CB, DGKA, INPP4A, ITPKB | More | | Sulfinpyrazone | hsa04071 | Sphingolipid signaling pathway | 5.59E-03 | 8 | P17252, Q9H228, P01375, Q13510, Q13362, Q9BX95, P10415, Q9UQC2 | PRKCA, EDG8, TNF, ASAH1, PPP2R5C, SGPP1, BCL2, GAB2 | More | | Sulfinpyrazone | hsa04072 | Phospholipase D signaling pathway | 3.63E-05 | 9 | P42338, Q92529, Q9UQC2, P19174, Q14344, Q8WYR1, Q08828, P23743, Q9NRA1 | PIK3CB, SHC3, GAB2, PLCG1, GNA13, PIK3R5, ADCY1, DGKA, PDGFC | More | | Sulfinpyrazone | hsa04151 | PI3K-Akt signaling pathway | 9.31E-05 | 17 | P42338, P43657, O43521, P20827, Q9NRA1, P49767, Q13362, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P23458, Q6ZUJ8, P30281 | PIK3CB, P2RY5, BCL2L11, EFNA1, PDGFC, VEGFC, PPP2R5C, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, JAK1, PIK3AP1, CCND3 | More | | Sulfinpyrazone | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | | Sulfinpyrazone | hsa04213 | Longevity regulating pathway - multiple species | 5.62E-04 | 4 | Q9Y4H2, Q08828, P0DMV8, Q13547 | IRS2, ADCY1, HSPA1A, HDAC1 | More | | Sulfinpyrazone | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | Sulfinpyrazone | hsa04217 | Necroptosis | 2.93E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | | Sulfinpyrazone | hsa04270 | Vascular smooth muscle contraction | 2.68E-02 | 3 | Q08828, P35579, P35318 | ADCY1, MYH9, ADM | More | | Sulfinpyrazone | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Sulfinpyrazone | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Sulfinpyrazone | hsa04370 | VEGF signaling pathway | 1.56E-02 | 2 | P19174, P42338 | PLCG1, PIK3CB | More | | Sulfinpyrazone | hsa04371 | Apelin signaling pathway | 4.48E-04 | 8 | P63218, P50151, Q8WYR1, Q13370, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, PDE3B, MEF2D, GNA13, SMAD4, SMAD3 | More | | Sulfinpyrazone | hsa04380 | Osteoclast differentiation | 9.58E-05 | 13 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, Q8N149, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, LILRA2, SIRPA | More | | Sulfinpyrazone | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | Sulfinpyrazone | hsa04510 | Focal adhesion | 1.55E-02 | 5 | P42338, O15335, Q9NRA1, P49767, Q92529 | PIK3CB, CHAD, PDGFC, VEGFC, SHC3 | More | | Sulfinpyrazone | hsa04540 | Gap junction | 2.03E-02 | 4 | P17252, P22694, P68371, Q02750 | PRKCA, PRKACB, TUBB2C, MAP2K1 | More | | Sulfinpyrazone | hsa04611 | Platelet activation | 1.59E-03 | 6 | Q9Y490, P42338, Q14344, Q08828, Q8WYR1, P07948 | TLN1, PIK3CB, GNA13, ADCY1, PIK3R5, LYN | More | | Sulfinpyrazone | hsa04613 | Neutrophil extracellular trap formation | 2.00E-03 | 18 | P11215, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P0C0S5, P58876, Q16778, O60814, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AFZ, H2BC5, HIST2H2BE, H2BC12, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Sulfinpyrazone | hsa04614 | Renin-angiotensin system | 7.48E-03 | 4 | P50052, P15144, P08311, O75787 | AGTR2, ANPEP, CTSG, ATP6AP2 | More | | Sulfinpyrazone | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | | Sulfinpyrazone | hsa04621 | NOD-like receptor signaling pathway | 5.00E-03 | 6 | P23458, P01568, Q9H3M7, Q13489, P43490, Q13546 | JAK1, IFNA21, TXNIP, BIRC3, PBEF1, RIPK1 | More | | Sulfinpyrazone | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Sulfinpyrazone | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Sulfinpyrazone | hsa04625 | C-type lectin receptor signaling pathway | 9.91E-04 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Sulfinpyrazone | hsa04640 | Hematopoietic cell lineage | 4.31E-02 | 10 | P13612, P14778, P27930, P15144, P11836, P09693, P01732, P13765, P01375, P01584 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD3G, CD8A, HLA-DOB, TNF, IL1B | More | | Sulfinpyrazone | hsa04650 | Natural killer cell mediated cytotoxicity | 2.87E-03 | 11 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O14931, O75015, P26717, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | | Sulfinpyrazone | hsa04657 | IL-17 signaling pathway | 9.91E-04 | 8 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | | Sulfinpyrazone | hsa04658 | Th1 and Th2 cell differentiation | 1.33E-05 | 14 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, P23458, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, JAK1, RUNX3 | More | | Sulfinpyrazone | hsa04659 | Th17 cell differentiation | 1.29E-05 | 18 | P25963, Q04759, Q16539, P19174, P06239, P14784, P13765, P14778, Q9UL17, P23771, P84022, Q13485, P01584, P08238, P07766, P09693, P20963, P23458 | NFKBIA, PRKCQ, MAPK14, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD3, SMAD4, IL1B, HSP90AB1, CD3E, CD3G, CD247, JAK1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | -0.728 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P06746 | POLB | DNA polymerase beta | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.787 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06746 | POLB | DNA polymerase beta | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.766 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.785 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.764 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.872 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.763 | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.769 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | O75469 | NR1I2 | Nuclear receptor subfamily 1 group I member 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.721 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P06746 | POLB | DNA polymerase beta | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.834 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P06746 | POLB | DNA polymerase beta | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.736 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.838 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 |
| Sulfinpyrazone | hsa04660 | T cell receptor signaling pathway | 4.52E-04 | 12 | P01375, Q04759, O95267, Q08881, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Sulfinpyrazone | hsa04662 | B cell receptor signaling pathway | 1.52E-03 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Sulfinpyrazone | hsa04664 | Fc epsilon RI signaling pathway | 1.98E-06 | 8 | P01375, Q16539, P42338, Q9UQC2, P07948, P19174, P09917, P20292 | TNF, MAPK14, PIK3CB, GAB2, LYN, PLCG1, ALOX5, ALOX5AP | More | | Sulfinpyrazone | hsa04666 | Fc gamma R-mediated phagocytosis | 1.73E-02 | 3 | P07948, P42338, P19174 | LYN, PIK3CB, PLCG1 | More | | Sulfinpyrazone | hsa04668 | TNF signaling pathway | 2.21E-02 | 5 | P01375, O00463, Q16539, P20749, P14780 | TNF, TRAF5, MAPK14, BCL3, MMP9 | More | | Sulfinpyrazone | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | | Sulfinpyrazone | hsa04720 | Long-term potentiation | 1.09E-02 | 4 | P17252, P51812, P22694, Q02750 | PRKCA, RPS6KA3, PRKACB, MAP2K1 | More | | Sulfinpyrazone | hsa04722 | Neurotrophin signaling pathway | 4.87E-02 | 3 | P42338, P19174, Q92529 | PIK3CB, PLCG1, SHC3 | More | | Sulfinpyrazone | hsa04724 | Glutamatergic synapse | 1.73E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | Sulfinpyrazone | hsa04725 | Cholinergic synapse | 1.24E-03 | 7 | P22694, P17252, P62879, P63218, P50151, P42338, Q02750 | PRKACB, PRKCA, GNB2, GNG5, GNG10, PIK3CB, MAP2K1 | More | | Sulfinpyrazone | hsa04726 | Serotonergic synapse | 2.20E-03 | 7 | P22694, P17252, P62879, P63218, P50151, P09917, Q02750 | PRKACB, PRKCA, GNB2, GNG5, GNG10, ALOX5, MAP2K1 | More | | Sulfinpyrazone | hsa04727 | GABAergic synapse | 5.05E-04 | 7 | P62879, P63218, P50151, P15104, P22694, O60296, P17252 | GNB2, GNG5, GNG10, GLUL, PRKACB, TRAK2, PRKCA | More | | Sulfinpyrazone | hsa04730 | Long-term depression | 1.56E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Sulfinpyrazone | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.17E-02 | 8 | P14778, P01584, P51828, P22694, Q16539, Q14643, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, MAPK14, ITPR1, PRKCQ, CALM2 | More | | Sulfinpyrazone | hsa04910 | Insulin signaling pathway | 4.11E-02 | 3 | Q92529, Q13370, P42338 | SHC3, PDE3B, PIK3CB | More | | Sulfinpyrazone | hsa04912 | GnRH signaling pathway | 4.33E-02 | 6 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB | More | | Sulfinpyrazone | hsa04914 | Progesterone-mediated oocyte maturation | 2.22E-02 | 3 | P42338, Q13370, P08238 | PIK3CB, PDE3B, HSP90AB1 | More | | Sulfinpyrazone | hsa04915 | Estrogen signaling pathway | 1.63E-04 | 7 | Q08828, P42338, Q92529, P08238, P0DMV8, P11142, Q15788 | ADCY1, PIK3CB, SHC3, HSP90AB1, HSPA1A, HSPA8, NCOA1 | More | | Sulfinpyrazone | hsa04919 | Thyroid hormone signaling pathway | 2.22E-02 | 5 | P17252, Q02750, P22694, Q12778, Q9UM47 | PRKCA, MAP2K1, PRKACB, FOXO1, NOTCH3 | More | | Sulfinpyrazone | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | | Sulfinpyrazone | hsa04921 | Oxytocin signaling pathway | 3.76E-02 | 3 | Q08828, Q96RR4, Q8WYR1 | ADCY1, CAMKK2, PIK3R5 | More | | Sulfinpyrazone | hsa04923 | Regulation of lipolysis in adipocytes | 3.64E-02 | 2 | Q13370, P42338 | PDE3B, PIK3CB | More | | Sulfinpyrazone | hsa04926 | Relaxin signaling pathway | 1.31E-03 | 5 | P42338, P63218, P50151, P49767, Q92529 | PIK3CB, GNG5, GNG10, VEGFC, SHC3 | More | | Sulfinpyrazone | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.48E-02 | 4 | P22694, Q02750, P17252, Q9Y5Q3 | PRKACB, MAP2K1, PRKCA, MAFB | More | | Sulfinpyrazone | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.54E-04 | 6 | P84022, Q13485, P10415, P42338, P49767, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PLCG1 | More | | Sulfinpyrazone | hsa04935 | Growth hormone synthesis, secretion and action | 2.78E-02 | 3 | P19174, P42338, Q92529 | PLCG1, PIK3CB, SHC3 | More | | Sulfinpyrazone | hsa04970 | Salivary secretion | 4.22E-02 | 3 | P22694, P17252, P49913 | PRKACB, PRKCA, CAMP | More | | Sulfinpyrazone | hsa04972 | Pancreatic secretion | 4.73E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | | Sulfinpyrazone | hsa04975 | Fat digestion and absorption | 9.50E-04 | 1 | O14494 | PLPP1 | More | | Sulfinpyrazone | hsa05032 | Morphine addiction | 2.22E-02 | 3 | P63218, P50151, Q13370 | GNG5, GNG10, PDE3B | More | | Sulfinpyrazone | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | | Sulfinpyrazone | hsa05100 | Bacterial invasion of epithelial cells | 3.64E-02 | 2 | P42338, Q92529 | PIK3CB, SHC3 | More | | Sulfinpyrazone | hsa05132 | Salmonella infection | 5.76E-04 | 7 | P25963, Q13546, Q13489, P10415, Q9BQS8, O60282, P68371 | NFKBIA, RIPK1, BIRC3, BCL2, FYCO1, KIF5C, TUBB2C | More | | Sulfinpyrazone | hsa05140 | Leishmaniasis | 2.29E-02 | 9 | P13612, O75015, P23458, P13765, O60603, P01375, P01584, Q16539, Q15080 | ITGA4, FCGR3B, JAK1, HLA-DOB, TLR2, TNF, IL1B, MAPK14, NCF4 | More | | Sulfinpyrazone | hsa05144 | Malaria | 2.43E-02 | 6 | P60033, O60603, P01375, P35443, P01584, P26718 | CD81, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Sulfinpyrazone | hsa05145 | Toxoplasmosis | 4.95E-04 | 6 | P25963, P10415, Q13489, P23458, Q8WYR1, P0DMV8 | NFKBIA, BCL2, BIRC3, JAK1, PIK3R5, HSPA1A | More | | Sulfinpyrazone | hsa05146 | Amoebiasis | 4.25E-02 | 9 | P01584, P09341, P14778, P27930, P01375, O60603, P05089, P22694, P08311 | IL1B, CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | | Sulfinpyrazone | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | | Sulfinpyrazone | hsa05162 | Measles | 2.81E-03 | 6 | P23458, P14784, P07766, P42338, P0DMV8, P11142 | JAK1, IL2RB, CD3E, PIK3CB, HSPA1A, HSPA8 | More | | Sulfinpyrazone | hsa05163 | Human cytomegalovirus infection | 1.10E-03 | 11 | P42338, P01375, P63218, P50151, Q14344, P49841, P14778, P25025, Q16539, O00463, P30101 | PIK3CB, TNF, GNG5, GNG10, GNA13, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5, PDIA3 | More | | Sulfinpyrazone | hsa05165 | Human papillomavirus infection | 4.71E-03 | 10 | P46527, Q02750, P35443, Q92796, Q05086, Q9UM47, P22694, Q13362, Q12778, Q13315 | CDKN1B, MAP2K1, THBS4, DLG3, UBE3A, NOTCH3, PRKACB, PPP2R5C, FOXO1, ATM | More | | Sulfinpyrazone | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.14E-02 | 5 | P42338, P63218, P50151, P19174, P07948 | PIK3CB, GNG5, GNG10, PLCG1, LYN | More | | Sulfinpyrazone | hsa05169 | Epstein-Barr virus infection | 3.34E-02 | 5 | P42338, P07948, P30101, Q13761, P07766 | PIK3CB, LYN, PDIA3, RUNX3, CD3E | More | | Sulfinpyrazone | hsa05170 | Human immunodeficiency virus 1 infection | 7.03E-03 | 6 | P42338, P63218, P50151, P30101, P19174, P07766 | PIK3CB, GNG5, GNG10, PDIA3, PLCG1, CD3E | More | | Sulfinpyrazone | hsa05200 | Pathways in cancer | 1.13E-03 | 17 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, IL2RB | More | | Sulfinpyrazone | hsa05202 | Transcriptional misregulation in cancer | 2.26E-04 | 20 | Q12778, Q13315, P17844, P14780, P27930, Q15744, Q16548, P11215, Q13077, P46527, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | FOXO1, ATM, DDX5, MMP9, IL1R2, CEBPE, BCL2A1, ITGAM, TRAF1, CDKN1B, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Sulfinpyrazone | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | | Sulfinpyrazone | hsa05206 | MicroRNAs in cancer | 3.66E-02 | 6 | P46527, Q9UM47, P16070, Q13315, P17252, Q02750 | CDKN1B, NOTCH3, CD44, ATM, PRKCA, MAP2K1 | More | | Sulfinpyrazone | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Sulfinpyrazone | hsa05212 | Pancreatic cancer | 9.87E-04 | 5 | P42338, P37173, P84022, Q13485, O75293 | PIK3CB, TGFBR2, SMAD3, SMAD4, GADD45B | More | | Sulfinpyrazone | hsa05214 | Glioma | 9.49E-03 | 3 | Q92529, P42338, P19174 | SHC3, PIK3CB, PLCG1 | More | | Sulfinpyrazone | hsa05215 | Prostate cancer | 4.87E-02 | 3 | Q9NRA1, P08238, P42338 | PDGFC, HSP90AB1, PIK3CB | More | | Sulfinpyrazone | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Sulfinpyrazone | hsa05218 | Melanoma | 3.64E-02 | 2 | Q9NRA1, P42338 | PDGFC, PIK3CB | More | | Sulfinpyrazone | hsa05220 | Chronic myeloid leukemia | 1.44E-03 | 6 | Q13547, Q13485, P25963, P84022, P42338, O75293 | HDAC1, SMAD4, NFKBIA, SMAD3, PIK3CB, GADD45B | More | | Sulfinpyrazone | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | | Sulfinpyrazone | hsa05226 | Gastric cancer | 2.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | Sulfinpyrazone | hsa05231 | Choline metabolism in cancer | 1.17E-03 | 4 | P42338, Q9NRA1, P19174, P23743 | PIK3CB, PDGFC, PLCG1, DGKA | More | | Sulfinpyrazone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.10E-02 | 8 | O95267, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539 | RASGRP1, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14 | More | | Sulfinpyrazone | hsa05321 | Inflammatory bowel disease | 1.21E-02 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | Sulfinpyrazone | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | | Sulfinpyrazone | hsa05418 | Fluid shear stress and atherosclerosis | 1.08E-03 | 7 | Q16539, Q14145, P10599, P14780, P01375, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2 | More | | |